# Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Study · id `cardio:ct-nct04419779` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04419779](<https://clinicaltrials.gov/study/NCT04419779>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04419779

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 320 participants.

## Technical summary

Registry record NCT04419779. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-08 (actual); primary completion 2026-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 320 participants (planned count; ClinicalTrials.gov record NCT04419779, source copy `cardio:ctgov-nct04419779-2025-11-13`, retrieved 2026-10-26)
- Started: 2021-03-08 (actual) (ClinicalTrials.gov record NCT04419779, source copy `cardio:ctgov-nct04419779-2025-11-13`, retrieved 2026-10-26)
- Primary completion: 2026-01 (anticipated) (ClinicalTrials.gov record NCT04419779, source copy `cardio:ctgov-nct04419779-2025-11-13`, retrieved 2026-10-26)
- Completion: 2026-01 (anticipated) (ClinicalTrials.gov record NCT04419779, source copy `cardio:ctgov-nct04419779-2025-11-13`, retrieved 2026-10-26)
- Countries: United States; Belgium; Ireland; Italy; Netherlands; Switzerland; United Kingdom (ClinicalTrials.gov record NCT04419779, source copy `cardio:ctgov-nct04419779-2025-11-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "SUSPENDED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04419779-2025-11-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes
- Acronym: REVITALIZE 1
- Condition: Type 2 Diabetes
- Intervention (Device): Duodenal Mucosal Resurfacing (DMR)
- Intervention (Device): Duodenal Mucosal Resurfacing (Sham)
- Lead sponsor: Fractyl Health Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 932d80360eb90c3e58788d7702dc16caf85e95a3bbe57d5ff5bac42035b21770
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
